News

Dacogen (decitabine) is a hypomethylating agent believed to exert its antineoplastic effects by incorporation into DNA and inhibition of an enzyme called DNA methyltransferase. Dacogen-induced hypomethylation in neoplastic

In exchange for those rights, Abbott Canada has agreed to a transfer price on product purchases and to make certain payments to Oscient upon achievement of certain regulatory

The proof-of-concept trial will test for analgesic activity and the safety of cannabinor (PRS-211,375), a CB2-selective synthetic cannabinoid drug candidate, in healthy subjects experiencing capsaicin-induced pain. In this

Mitsubishi Pharma extensively developed the compound, named BCI-540, for another central nervous system (CNS) indication, but suspended the program when the drug met safety expectations but did not

In the course of the collaboration, Evotec will develop assays, including those designed for high content screening, against high priority biological targets thought to be of importance in

Under the terms of the deal, Sofgen is responsible for the formulation and development of the drug, the manufacture of clinical product batches, and the documentation necessary to

In March 2006, Pharming announced a heads of agreement with DNage to acquire all shares of the biopharmaceutical company. However, during the acquisition process, the Works Council of

The phase I study is an open-label, multi-center trial designed to establish the maximum tolerated dose (MTD) for oral PXD101 administered once or twice daily. Patients will be

Protox also reported that the University of Vermont will participate in the clinical trial, joining Scott & White Memorial Hospital, the lead center in the trial, which began